Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

AEGIS-H2H study results published in Inflammatory Bowel Diseases

18 May 2021

Shield Therapeutics plc, notes the recent publication in the journal Inflammatory Bowel Diseases of positive long-term results from a study comparing the effectiveness of ferric maltol 30 mg bid with intravenous (IV) iron (ferric carboxymaltose given according to each centre’s standard practice) over 52 weeks. The primary endpoint was haemoglobin responder rate (≥2 g/dL increase or normalization) at week 12, with a 20% noninferiority limit in the intent-to-treat and per protocol populations.

For further details click here.

Back to news